Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VAC 40
- Development stage
- Unknown
- Lead developer
- MEDcell
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
VAC 40 is an oral fixed-dose combination nutraceutical developed by Medcell Pharma for the management of premenstrual syndrome (PMS), premenstrual dysphoric disorder (PMDD), and cyclic mastalgia (breast pain). It contains Vitex agnus-castus (chasteberry) fruit extract (40 mg), pyridoxine (vitamin B6, 1.9 mg), and magnesium oxide (250 mg). Vitex agnus-castus acts as a dopamine D2 receptor agonist, which suppresses pituitary prolactin secretion, thereby alleviating prolactin-mediated symptoms such as breast tenderness and menstrual irregularity. Pyridoxine serves as a cofactor in neurotransmitter synthesis (serotonin, dopamine, GABA) to regulate mood and anxiety, while magnesium oxide acts as an NMDA receptor antagonist and calcium channel blocker to relieve physical symptoms like muscle cramps and abdominal pain.
- Brand names
- VAC 40VAC40VAC-40Vac 40 TabletVac40 TabletVac-40 Tablet
- Other names
- chasteberry extract + vitamin B6 + magnesium oxideVitex agnus-castus extract + pyridoxine + magnesium oxideVitex agnus-castus fruit extract + vitamin B6 + magnesium oxide
02
Targets
DDC (Aromatic L-amino acid decarboxylase)DRD2 (Dopamine D2 Receptor)NMDAR (Glutamate receptor ionotropic, NMDA)
Beyond the preview
Go deeper on VAC 40.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VAC 40.